Neuromodulation of the inflammatory reflex has produced encouraging early data in rheumatoid arthritis, mostly via vagus nerve stimulation. This first-in-human pilot tested percutaneous sacral nerve stimulation delivered through acupuncture needles, randomising 21 patients with active disease to active stimulation or sham for 60 minutes daily over 14 days.
The active group showed significant within-group improvements in tender joint count, pain score and both DAS28 measures. But analysis of covariance adjusting for baseline values found no significant between-group differences in any clinical or inflammatory parameter. The one difference that survived adjustment was physiological rather than clinical: a significant increase in rMSSD, a heart rate variability marker of parasympathetic activity. Serum cytokines, function and psychological scores did not differ. No serious adverse events occurred.
The within-group versus between-group contrast is the whole story, and it is why sham-controlled designs matter. Patients receiving daily attention and a plausible intervention improve; the sham group did too. What the trial establishes is feasibility, safety, and evidence that the intervention does what it is mechanistically supposed to do to the autonomic nervous system. It establishes nothing about whether that translates into treating arthritis, and with 21 patients it was never going to.
- Significant within-group improvement in DAS28, tender joints and pain
- No significant between-group difference after adjusting for baseline
- Parasympathetic marker rMSSD did increase versus sham
- 21 patients; safe and feasible, efficacy untested
The statistics, in plain English
Within-group improvement means patients were better than they started; between-group difference means the treatment beat the sham. Only the second answers whether the intervention works, and reporting the first prominently is one of the commonest ways small trials read as more positive than they are. With 11 and 10 patients per arm, this trial could only have detected an enormous effect, so the negative result is uninformative about efficacy rather than evidence against it.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free